What is Luxturna therapy and who developed it?

Luxturna is the first approved gene therapy for inherited blindness, developed by molecular biologist Jean Bennett and ophthalmologist Albert Maguire.

What condition does Luxturna therapy treat?

Luxturna therapy treats Leber congenital amaurosis (LCA), a genetic disorder that typically causes total blindness by early adulthood.

What impact has the Luxturna therapy had?

The therapy has transformed lives, allowing patients to see loved ones and experience profound visual improvements.

Home / Science / Couple's Blindness Gene Therapy Earns $3M Breakthrough Prize

Couple's Blindness Gene Therapy Earns $3M Breakthrough Prize

19 Apr

•

Summary

Luxturna therapy, developed by a married couple, offers hope for inherited blindness.
The breakthrough earned Jean Bennett and Albert Maguire a $3m science prize.
The therapy has transformed lives, allowing patients to see loved ones.

Couple's Blindness Gene Therapy Earns $3M Breakthrough Prize

Molecular biologist Jean Bennett and ophthalmologist Albert Maguire have been awarded the $3 million Breakthrough Prize in Life Sciences for their development of Luxturna, the first approved gene therapy for inherited blindness. The therapy targets Leber congenital amaurosis (LCA), a genetic disorder causing blindness. Its success was evidenced in clinical trials where patients described profound visual improvements, including seeing their children's faces for the first time.